Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review)
- Authors:
- Andrea Lampis
- Margherita Ratti
- Michele Ghidini
- Milko B. Mirchev
- Ali Fuat Okuducu
- Nicola Valeri
- Jens Claus Hahne
-
Affiliations: Division of Molecular Pathology, The Institute of Cancer Research, Sutton SM25NG, UK, Division of Medical Oncology, Hospital Policlinic ‘Fondazione IRCCS Ca' Granda Ospedale Maggiore’, I-20122 Milan, Italy, Clinic of Gastroenterology, Medical University, 9002 Varna, Bulgaria, Pathology Länggasse, 3063 Bern, Switzerland - Published online on: April 8, 2021 https://doi.org/10.3892/ijmm.2021.4930
- Article Number: 97
-
Copyright : © Lampis et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
de Vos-Geelen J, Hoebers FJP, Geurts SME, Hoeben A, de Greef BTA, Voncken FEM, Bogers JHA, Braam PM, Muijs CKT, de Jong MA, et al: A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol. 59:895–903. 2020. View Article : Google Scholar : PubMed/NCBI | |
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Feb 4–2021.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 23:233–242. 2013. View Article : Google Scholar : PubMed/NCBI | |
Napier KJ, Scheerer M and Misra S: Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI | |
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB III, Carrato A, Gulley ML, Jain D, Kakar S, et al: HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: Guideline from the college of American pathologists American society for clinical pathology, and American society of clinical oncology. Arch Pathol Lab Med. 140:1345–1363. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
Lordick F, Mariette C, Haustermans K, Obermannova R and Arnold D; ESMO Guidelines Committee: Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27(Suppl 5): v50–v57. 2016. View Article : Google Scholar : PubMed/NCBI | |
Brar G and Shah MA: The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol. 12:17562848198697672019. View Article : Google Scholar : PubMed/NCBI | |
Le Bras GF, Farooq MH, Falk GW and Andl CD: Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res. 113(Pt A): 236–244. 2016. View Article : Google Scholar : PubMed/NCBI | |
Short MW, Burgers KG and Fry VT: Esophageal cancer. Am Fam Physician. 95:22–28. 2017.PubMed/NCBI | |
Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al: Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus. 16:25–43. 2019. View Article : Google Scholar : | |
Wang T, Yu J, Liu M, Chen Y, Zhu C, Lu L, Wang M, Min L, Liu X, Zhang X, et al: The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: A meta-analysis of clinical studies. Drug Des Devel Ther. 13:539–553. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI | |
Blot WJ: Invited commentary: More evidence of increased risks of cancer among alcohol drinkers. Am J Epidemiol. 150:1138–1140; discussion 1141. 1999. View Article : Google Scholar : PubMed/NCBI | |
Guanrei Y and Songliang Q: Endoscopic surveys in high-risk and low-risk populations for esophageal cancer in China with special reference to precursors of esophageal cancer. Endoscopy. 19:91–95. 1987. View Article : Google Scholar : PubMed/NCBI | |
Lagergren J and Lagergren P: Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 63:232–248. 2013. View Article : Google Scholar : PubMed/NCBI | |
Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ and Vaughan TL: Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 11:934–943. 2013. View Article : Google Scholar : PubMed/NCBI | |
Carr JS, Zafar SF, Saba N, Khuri FR and El-Rayes BF: Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer. 44:143–151. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lofdahl HE, Lu Y, Lagergren P and Lagergren J: Risk factors for esophageal adenocarcinoma after antireflux surgery. Ann Surg. 257:579–582. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mao WM, Zheng WH and Ling ZQ: Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev. 12:2461–2466. 2011. | |
D'Onofrio V, Bovero E and Iaquinto G: Characterization of acid and alkaline reflux in patients with Barrett's esophagus. G.O.S.P.E. Operative Group for the study of Esophageal Precancer. Dis Esophagus. 10:16–22; discussion 22-3. 1997.PubMed/NCBI | |
Fassan M, Realdon S, Cascione L, Hahne JC, Munari G, Guzzardo V, Arcidiacono D, Lampis A, Brignola S, Dal Santo L, et al: Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrett's carcinogenesis. Pathol Res Pract. 216:1529072020. View Article : Google Scholar : PubMed/NCBI | |
Lin J, Zeng R, Cao W, Luo R, Chen J and Lin Y: Hot beverage and food intake and esophageal cancer in southern China. Asian Pac J Cancer Prev. 12:2189–2192. 2011. | |
Nieman KM, Romero IL, Van Houten B and Lengyel E: Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499:214–218. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ratti M, Lampis A, Hahne JC, Passalacqua R and Valeri N: Microsatellite instability in gastric cancer: Molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 75:4151–4162. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lin EW, Karakasheva TA, Hicks PD, Bass AJ and Rustgi AK: The tumor microenvironment in esophageal cancer. Oncogene. 35:5337–5349. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ammannagari N and Atasoy A: Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. J Gastrointest Oncol. 9:196–207. 2018. View Article : Google Scholar : PubMed/NCBI | |
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 Blockade in tumors with Mismatch-Repair deficiency. N Engl J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kim WK, Park M, Park M, Kim YJ, Shin N, Kim HK, You KT and Kim H: Identification and selective degradation of neopeptide-containing truncated mutant proteins in the tumors with high microsatellite instability. Clin Cancer Res. 19:3369–3382. 2013. View Article : Google Scholar : PubMed/NCBI | |
Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, et al: The immune revolution in gastrointestinal tumours: Leading the way or just following? Target Oncol. 11:593–603. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li P, Xu W, Liu F, Zhu H, Zhang L, Ding Z, Liang H and Song J: The emerging roles of IDO2 in cancer and its potential as a therapeutic target. Biomed Pharmacother. 137:1112952021. View Article : Google Scholar : PubMed/NCBI | |
Zhou H, Jiang M, Yuan H, Ni W and Tai G: Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer. Oncol Lett. 21:1492021. View Article : Google Scholar : PubMed/NCBI | |
Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, Buart S, Szczylik C, Kieda C and Chouaib S: Tumor hypoxia regulates immune Escape/Invasion: Influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies. Front Immunol. 11:6131142021. View Article : Google Scholar : PubMed/NCBI | |
Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ando M, Ito M, Srirat T, Kondo T and Yoshimura A: Memory T cell, exhaustion, and tumor immunity. Immunol Med. 43:1–9. 2020. View Article : Google Scholar | |
Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hahne JC, Meyer SR, Gambaryan S, Walter U, Dietl J, Engel JB and Honig A: Immune escape of AKT overexpressing ovarian cancer cells. Int J Oncol. 42:1630–1635. 2013. View Article : Google Scholar : PubMed/NCBI | |
Boutet P, Aguera-Gonzalez S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómez M: Cutting edge: The metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol. 182:49–53. 2009. View Article : Google Scholar | |
Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG and Steinle A: Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI | |
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, et al: Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 4:eaar27662018. View Article : Google Scholar : PubMed/NCBI | |
Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE and Whiteside TL: Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 24:896–905. 2018. View Article : Google Scholar | |
Corthay A: How do regulatory T cells work? Scand J Immunol. 70:326–336. 2009. View Article : Google Scholar : PubMed/NCBI | |
Romano M, Fanelli G, Albany CJ, Giganti G and Lombardi G: Past, present, and future of regulatory T Cell therapy in transplantation and autoimmunity. Front Immunol. 10:432019. View Article : Google Scholar : PubMed/NCBI | |
Togashi Y, Shitara K and Nishikawa H: Regulatory T cells in cancer immunosuppression-implications for anticancer therapy. Nat Rev Clin Oncol. 16:356–371. 2019. View Article : Google Scholar : PubMed/NCBI | |
Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J and Segerer SE: Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet. 289:141–147. 2014. View Article : Google Scholar | |
Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI | |
Gabrilovich DI: Myeloid-Derived suppressor cells. Cancer Immunol Res. 5:3–8. 2017. View Article : Google Scholar : PubMed/NCBI | |
Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, Lee JW, Beatty GL, Gabrilovich DI and Rustgi AK: CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight. 3:e970222018. View Article : Google Scholar : | |
Shi T, Ma Y, Yu L, Jiang J, Shen S, Hou Y and Wang T: Cancer immunotherapy: A focus on the regulation of immune check- points. Int J Mol Sci. 19:13892018. View Article : Google Scholar | |
Kim ES, Kim JE, Patel MA, Mangraviti A, Ruzevick J and Lim M: Immune checkpoint modulators: An emerging anti-glioma armamentarium. J Immunol Res. 2016:46836072016. View Article : Google Scholar | |
Vivaldi C, Catanese S, Massa V, Pecora I, Salani F, Santi S, Lencioni M, Vasile E, Falcone A and Fornaro L: Immune check-point inhibitors in esophageal cancers: Are we finally finding the right path in the mist? Int J Mol Sci. 21:16582020. View Article : Google Scholar | |
Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI | |
Topalian SL, Drake CG and Pardoll DM: Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI | |
Disis ML: Mechanism of action of immunotherapy. Semin Oncol. 41(Suppl 5): S3–S13. 2014. View Article : Google Scholar : PubMed/NCBI | |
Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, et al: Effect of IL-18 on the expansion and phenotype of human natural killer cells: Application to cancer immunotherapy. Int J Biol Sci. 14:331–340. 2018. View Article : Google Scholar : PubMed/NCBI | |
Patel SP and Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI | |
Mimura K, Yamada L, Ujiie D, Hayase S, Tada T, Hanayama H, Thar Min AK, Shibata M, Momma T, Saze Z, et al: Immunotherapy for esophageal squamous cell carcinoma: A review. Fukushima J Med Sci. 64:46–53. 2018. View Article : Google Scholar : PubMed/NCBI | |
Redman JM, Gibney GT and Atkins MB: Advances in immunotherapy for melanoma. BMC Med. 14:202016. View Article : Google Scholar : PubMed/NCBI | |
Figueroa-Protti L, Soto-Molinari R, Calderon-Osorno M, Mora J and Alpizar-Alpizar W: Gastric cancer in the Era of immune checkpoint blockade. J Oncol. 2019:10797102019. View Article : Google Scholar : PubMed/NCBI | |
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI | |
Marchetti A, Di Lorito A and Buttitta F: Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle. J Thorac Dis. 9:4863–4866. 2017. View Article : Google Scholar | |
Akinleye A and Rasool Z: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12:922019. View Article : Google Scholar : PubMed/NCBI | |
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI | |
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al: Anti-progra mmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117. 2014. View Article : Google Scholar : PubMed/NCBI | |
Maleki Vareki S, Garrigos C and Duran I: Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 116:116–124. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, et al: Increased Tim-3(+) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother. 5467:1673–1683. 2018. View Article : Google Scholar | |
Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 18:1600–1609. 2017. View Article : Google Scholar : PubMed/NCBI | |
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17:956–965. 2016. View Article : Google Scholar : PubMed/NCBI | |
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 4:e1800132018. View Article : Google Scholar : PubMed/NCBI | |
Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M and Bennouna J: Safety and antitumor activity of the Anti-Programmed Death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 36:61–67. 2018. View Article : Google Scholar | |
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al: Safety and antitumor activity of Anti-PD-1 Antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 33:4015–4022. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al: Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20:1506–1517. 2019. View Article : Google Scholar : PubMed/NCBI | |
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV and Dhodapkar KM: Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 194:950–959. 2015. View Article : Google Scholar | |
Tanaka T, Nakamura J and Noshiro H: Promising immunotherapies for esophageal cancer. Expert Opin Biol Ther. 17:723–733. 2017. View Article : Google Scholar : PubMed/NCBI | |
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, et al: CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. 36:2836–2844. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhao Y, Yang W, Huang Y, Cui R, Li X and Li B: Evolving roles for Targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 47:721–734. 2018. View Article : Google Scholar : PubMed/NCBI | |
Darvin P, Toor SM, Sasidharan Nair V and Elkord E: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI | |
Rosenberg SA and Restifo NP: Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348:62–68. 2015. View Article : Google Scholar : PubMed/NCBI | |
Alsina M, Moehler M and Lorenzen S: Immunotherapy of esophageal cancer: Current status, many trials and innovative strategies. Oncol Res Treat. 41:266–271. 2018. View Article : Google Scholar : PubMed/NCBI | |
Miliotou AN and Papadopoulou LC: CAR T-cell Therapy: A New Era in cancer immunotherapy. Curr Pharm Biotechnol. 19:5–18. 2018. View Article : Google Scholar : PubMed/NCBI | |
Walseng E, Koksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM and Wälchli S: A TCR-based Chimeric antigen receptor. Sci Rep. 7:107132017. View Article : Google Scholar : PubMed/NCBI | |
Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ Jr and Rosenberg SA: Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 173:7125–7130. 2004. View Article : Google Scholar : PubMed/NCBI | |
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 26:5233–5239. 2008. View Article : Google Scholar : PubMed/NCBI | |
Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K and Itoh K: Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res. 6:4663–4673. 2000. | |
Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, et al: Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res. 21:2268–2277. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li W, Joshi MD, Singhania S, Ramsey KH and Murthy AK: Peptide vaccine: Progress and challenges. Vaccines (Basel). 2:515–536. 2014. View Article : Google Scholar | |
Masopust D and Schenkel JM: The integration of T cell migration, differentiation and function. Nat Rev Immunol. 13:309–320. 2013. View Article : Google Scholar : PubMed/NCBI | |
Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G and Galluzzi L: Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2:e266212013. View Article : Google Scholar | |
Tacken PJ, de Vries IJ, Torensma R and Figdor CG: Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat Rev Immunol. 7:790–802. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hos BJ, Tondini E, van Kasteren SI and Ossendorp F: Approaches to improve chemically defined synthetic peptide vaccines. Front Immunol. 9:8842018. View Article : Google Scholar : PubMed/NCBI | |
Chen DS and Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature. 541:321–330. 2017. View Article : Google Scholar : PubMed/NCBI | |
Blander JM: Regulation of the cell biology of antigen cross-presentation. Annu Rev Immunol. 36:717–753. 2018. View Article : Google Scholar : PubMed/NCBI | |
Quakkelaar ED and Melief CJ: Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol. 114:77–106. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kono K: Current status of cancer immunotherapy. J Stem Cells Regen Med. 10:8–13. 2014. View Article : Google Scholar : PubMed/NCBI | |
Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y, et al: Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother. 35:513–521. 2012. View Article : Google Scholar : PubMed/NCBI | |
Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response. Clin Cancer Res. 21:1019–1027. 2015. View Article : Google Scholar | |
Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, Matsuzaki J, Tsuji T, Groman A, Gnjatic S, et al: Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 9:e1040992014. View Article : Google Scholar : PubMed/NCBI | |
Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, et al: Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer. 120:2178–2184. 2007. View Article : Google Scholar : PubMed/NCBI | |
Veit JA, Heine D, Thierauf J, Lennerz J, Shetty S, Schuler PJ, Whiteside T, Beutner D, Meyer M, Grünewald I, et al: Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head Neck. 38:1008–1016. 2016. View Article : Google Scholar : PubMed/NCBI | |
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D and Decock J: NY-ESO-1 based immunotherapy of cancer: Current perspectives. Front Immunol. 9:9472018. View Article : Google Scholar : PubMed/NCBI | |
Bujas T, Marusic Z, Peric Balja M, Mijic A, Kruslin B and Tomas D: MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma. Eur J Histochem. 55:e72011. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Zhou X, Liu D, Zhu Y, Ma Q and Zhang Y: Progress and challenges of poersonalized neoantigens in the clinical treatment of tumors. Med Drug Disc. 6:1000302020. View Article : Google Scholar | |
Huang TX and Fu L: The immune landscape of esophageal cancer. Cancer Commun (Lond). 39:792019. View Article : Google Scholar | |
Tran E, Robbins PF and Rosenberg SA: 'Final common pathway' of human cancer immunotherapy: Targeting random somatic mutations. Nat Immunol. 18:255–262. 2017. View Article : Google Scholar : PubMed/NCBI | |
Butterfield LH: Cancer vaccines. BMJ. 350:h9882015. View Article : Google Scholar : PubMed/NCBI | |
Han XJ, Ma XL, Yang L, Wei YQ, Peng Y and Wei XW: Progress in neoantigen targeted cancer immunotherapies. Front Cell Dev Biol. 8:7282020. View Article : Google Scholar : PubMed/NCBI | |
Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S and Zhou C: Tumor neoantigens: From basic research to clinical applications. J Hematol Oncol. 12:932019. View Article : Google Scholar : PubMed/NCBI | |
Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547:222–226. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI | |
Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, et al: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 12:842014. View Article : Google Scholar : PubMed/NCBI | |
Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, et al: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 10:1412012. View Article : Google Scholar : PubMed/NCBI | |
Yasuda T, Nishiki K, Yoshida K, Shiraishi O, Iwama M, Kato H, Yasuda A, Shinkai M, Chiba Y, Okuno K and Nakamura Y: Cancer peptide vaccine to suppress postoperative recurrence in esophageal SCC patients with induction of antigen-specific CD8+T cell. J Clin Oncol. 35(Suppl 15): e146352017. View Article : Google Scholar | |
Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, Marumoto T, Takahashi A, Okazaki T, Takeda K, et al: Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 166-167:48–58. 2016. View Article : Google Scholar : PubMed/NCBI | |
Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, et al: HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer. 123:2616–2625. 2008. View Article : Google Scholar : PubMed/NCBI | |
Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, et al: A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Ann Oncol. 28:798–803. 2017. View Article : Google Scholar | |
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, et al: Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 21:312–321. 2015. View Article : Google Scholar | |
Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, et al: Virotherapy research in Germany: From engineering to translation. Hum Gene Ther. 28:800–819. 2017. View Article : Google Scholar : PubMed/NCBI | |
Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR and Rommelaere J: Oncolytic virotherapy as emerging immunotherapeutic modality: Potential of parvovirus h-1. Front Oncol. 4:922014. View Article : Google Scholar : PubMed/NCBI | |
Conry RM, Westbrook B, McKee S and Norwood TG: Talimogene laherparepvec: First in class oncolytic virotherapy. Hum Vaccin Immunother. 14:839–846. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tanabe S, Tazawa H, Kagawa S, Noma K, Takehara K, Koujima T, Kashima H, Kato T, Kuroda S, Kikuchi S, et al: Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in elderly esophageal cancer patients. Cancer Res. 75:Abstract CT1232015. | |
Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, et al: A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 18:429–434. 2010. View Article : Google Scholar : | |
Sharabi AB, Lim M, DeWeese TL and Drake CG: Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI | |
Humphries MP, Craig SG, Kacprzyk R, Fisher NC, Bingham V, McQuaid S, Murray GI, McManus D, Turkington RC, James J and Salto-Tellez M: The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer. 20:5002020. View Article : Google Scholar : PubMed/NCBI |